Journal
APPLIED SCIENCES-BASEL
Volume 11, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/app11030898
Keywords
chaperone system; molecular chaperones; chaperonopathies; nervous system; neurochaperonopathies; Hsps; neurodegeneration; neuromuscular disorders; chaperonotherapy
Categories
Funding
- IMET
- IEMEST
Ask authors/readers for more resources
The chaperone system plays a critical role in maintaining protein quality control, with dysfunctions leading to chaperonopathies that impact various tissues and organs throughout the body. Neurochaperonopathies are divided into genetic and acquired forms, associated with different abnormal molecular chaperones. Awareness of the impact of chaperonopathies on diseases can improve diagnosis and treatment options.
The chaperone (or chaperoning) system (CS) constitutes molecular chaperones, co-chaperones, and chaperone co-factors, interactors and receptors, and its canonical role is protein quality control. A malfunction of the CS may cause diseases, known as the chaperonopathies. These are caused by qualitatively and/or quantitatively abnormal molecular chaperones. Since the CS is ubiquitous, chaperonopathies are systemic, affecting various tissues and organs, playing an etiologic-pathogenic role in diverse conditions. In this review, we focus on chaperonopathies involved in the pathogenic mechanisms of diseases of the central and peripheral nervous systems: the neurochaperonopathies (NCPs). Genetic NCPs are linked to pathogenic variants of chaperone genes encoding, for example, the small Hsp, Hsp10, Hsp40, Hsp60, and CCT-BBS (chaperonin-containing TCP-1- Bardet-Biedl syndrome) chaperones. Instead, the acquired NCPs are associated with malfunctional chaperones, such as Hsp70, Hsp90, and VCP/p97 with aberrant post-translational modifications. Awareness of the chaperonopathies as the underlying primary or secondary causes of disease will improve diagnosis and patient management and open the possibility of investigating and developing chaperonotherapy, namely treatment with the abnormal chaperone as the main target. Positive chaperonotherapy would apply in chaperonopathies by defect, i.e., chaperone insufficiency, and consist of chaperone replacement or boosting, whereas negative chaperonotherapy would be pertinent when a chaperone actively participates in the initiation and progression of the disease and must be blocked and eliminated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available